European Psychiatry

Editorial Policies


Manuscripts are accepted for consideration by European Psychiatry with the understanding that they represent original material, have not been published previously, are not being considered for publication elsewhere, and have been approved by each author. Manuscripts on clinical trials will only be considered if reporting on trials registered in a public trials registry.

Prior Publication

Prior publication is any form of publication other than a conference abstract of 400 words or less. Prior publication includes books or chapters, invited articles, or reports regardless of the format of publication (print or digital). Authors submitting manuscripts containing data that have been used in published (either in print or online) or in submitted articles should inform the Editors in the cover letter and explain why the submission to European Psychiatry merits an independent report. Authors must identify figures, tables, and/or data that have been published elsewhere, and permission from the copyright holder must be obtained to reproduce or modify the materials.

Clinical Trial Registration

In concordance with the IJCME, European Psychiatry only considers clinical trials registered in a public trials registry. For this purpose, the ICMJE defines a clinical trial as any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes. Health-related interventions include any intervention used to modify a biomedical or health-related outcome (for example, drugs, surgical procedures, devices, behavioral treatments, dietary interventions, and process-of-care changes). Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) do not require registration. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (for example, phase I trials), are exempt. All clinical trials, regardless of when they were completed, must be registered before submission of a manuscript based on the trial. The trial name, URL, and registration number should be included at the end of the abstract. Acceptable registries are ClinicalTrials.gov (http://www.clinicaltrials.gov) or any primary registries in the World Health Organization International Clinical Trials Registry Platform (http://www.who.int/ictrp/network/primary/en/index.html) (e.g. Australian New Zealand Clinical Trials Registry; ISRCTN Register; Nederlands Trial Register; UMIN Clinical Trials Registry).
Criteria of Authorship Credit
Authorship credit should be based on substantial contributions to 1) conception and design or analysis and interpretation of data, 2) drafting the article or revising it critically for important intellectual content, and on 3) final approval of the version to be published. Conditions 1, 2, and 3 must all be met. Each author should have participated sufficiently in the work to take public responsibility for the content. Only those with key responsibility for the material in the article should be listed as authors; others contributing to the work should be listed in Acknowledgements. As this may infer endorsement, all persons included in Acknowledgements must give written permission for their inclusion. It is the corresponding author's responsibility to obtain written permission. The same principles apply to manuscripts by groups or committees. Individuals meeting authorship criteria should be listed as authors followed by the name of the group or committee. Other contributing authors, who may also be contributing members of the group or committee, should be listed in Acknowledgements. Individuals whose contribution was based solely on 1) acquisition of funding, 2) general oversight of a research group/study, or 3) the collection of data do not qualify for authorship. Requests to change the corresponding author or to add/delete any authors must be submitted directly to the Editorial Office.

Corresponding Author
There can be only one corresponding author. European Psychiatry assumes that by acting as the corresponding author, the author acknowledges and accepts the following responsibilities: 1) act as the sole correspondent with the Editorial Office and the publisher, Elsevier, on all matters related to the submission, including review and correction of the typeset proof; 2) assurance that all individuals who meet the criteria for authorship are included as authors on the manuscript title page, and that the version submitted is the version that all authors have approved; and 3) assurance that written permission has been received from all individuals whose contributions to the work are included in the Acknowledgments section of the manuscript.

Funding and other support
Authors must declare sources of study funding including sponsorship (e.g. university, charity, commercial organization) and sources of material (e.g. novel drugs) not available commercially.

Conflict of Interest
The journal policy on disclosure is aligned to the policies of the ICMJE and other such organizations. Authors must disclose any commercial or financial involvements that might present an appearance of a conflict of interest in connection with the submitted article, including but not limited to institutional or corporate affiliations not already specified in the author's footnote, paid consultancies, stock ownership or other equity interests, patent ownership, royalties from rating scales, inventions, therapy methods, and funds for travel. Such involvements will not be grounds for automatic rejection of the manuscript. Sample text for disclosure: “Dr. X received lecture fees from ABC Pharmaceutical, research funding from CBA Ltd and consulting fees from AB Labs. Dr. Y reports patent and stock ownership in connection to Gtest and Gtherapeutics. Dr. Z reports no biomedical financial interests or potential conflicts of
interest.” This information will be published with the article, if accepted. A disclosure of competing interests form, available here, must be signed by all authors upon acceptance of the paper.

**Ethical and Legal Considerations**

**Patient Anonymity**
Patient anonymity must be protected in all cases. Identifying information such as names, initials, hospital numbers, dates, and any information about the patient’s characteristics or personal history that may result in personal identification should be removed.

**Ethical Approval and Informed Consent**
Any study that reports results based on direct contact with human subjects (regardless of the procedures used) must include a statement that ethical approval was obtained for the study and that written informed consent was obtained from participants after the procedure(s) had been fully explained. Studies on vulnerable adult populations (e.g., prisoners, cognitively impaired individuals) should also describe the process of assessing capacity and safeguards that were in place to protect study participants. Studies that use archival information on human subjects (e.g., electronic medical records, research databases, national registries) should include information about the ethical framework of the study and specify whether anonymized or de-identified data were used. In the case of children, the authors should include information about whether the child's assent was obtained. Submissions that do not contain the relevant information on ethical approval and consent will not be reviewed.

**Care of Animals**
Studies reporting experiments on animals should include a statement that institutional and national guidelines for the care and use of laboratory animals were followed.

**Scientific Integrity and Misconduct**
European Psychiatry will pursue any allegations of misconduct, including but not limited to plagiarism, duplicate submission or publication, data fabrication or falsification, unethical treatment of research subjects, authorship disputes, and undisclosed conflicts of interest. The Journal generally follows the guidelines recommended by the Committee on Publication Ethics (http://publicationethics.org/). Depending on the nature of the problem, we reserve the right to take action as deemed necessary, including contacting the authors' institution(s), funding agency, or other appropriate authority for investigation. Literature corrections, via errata or retractions, are handled on a case-by-case basis.
RESEARCH AND DATA REPORTING

European Psychiatry expects that submitted papers will meet high standards of data reporting. Authors should submit internationally adopted checklists for study designs, including randomized controlled trials (CONSORT), systematic reviews (PRISMA), meta-analyses of observational studies (MOOSE), and diagnostic accuracy studies (STARD). Particularly, authors are required to submit CONSORT materials (flow diagram and checklist) for all randomized controlled trials. In addition, the Minimum Information for Biological and Biomedical Investigations (MIBBI) portal also provides data-reporting standards, such as MIAME for microarray experiments. A comprehensive list of reporting guidelines is available from the EQUATOR Network Library (http://www.equator-network.org). Authors should make use of the appropriate guidelines when drafting their papers. Peer reviewers are asked to refer to these checklists when evaluating these studies.

For genetic studies, authors should use approved nomenclature for gene symbols by consulting the appropriate public databases for correct gene names and symbols. GenBank/EMBL accession numbers for primary nucleotide and amino acid sequence data should be included in the manuscript at the end of the Methods and Materials section.

REPOSITORY DATA

A growing number of private and public repositories are accumulating demographic and clinical data, genetic and genetic analysis data, DNA, and other biomaterials for use in medical research. Manuscripts submitted for publication in European Psychiatry that employ repository data and/or biomaterials must be in full compliance with the rules developed by the respective repository governing the correct citation of the repository, funding agencies, and investigators who contributed to the repository. Any other stipulation by the repository governing publications using repository data and/or biomaterials must also be followed. Authors must provide sufficient information in the manuscript for the Editor and reviewers to determine that these conditions have been met and that the repository has been established and maintained according to current ethical standards. The Editors may require authors to provide additional documentation regarding the repository during the review process.

FUNDING BODY AGREEMENTS

Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier to comply with manuscript archiving requirements of multiple funding bodies, including the National Institutes of Health and Wellcome Trust. Please see the full details at www.elsevier.com/fundingbodyagreements.

Authors retain the following rights: 1) Patent and trademark rights and rights to any process or procedure described in the article. 2) The right to photocopy or make single electronic copies of the article for their own personal use, including for their own classroom use, or for the personal use of colleagues, provided the copies are not offered for sale and are not distributed in a systematic way.
outside of their employing institution (e.g. via an e-mail list or public file server). Posting of the article on a secure network (not accessible to the public) within the author's institute is permitted. However, if a prior version of this work (normally a preprint) has been posted to an electronic public server, the author(s) agree not to update and/or replace this prior version on the server in order to make it identical in content to the final published version, and further that posting of the article as published on a public server can only be done with Elsevier's written permission. 3) The right, subsequent to publication, to use the article or any part thereof free of charge in a printed compilation of works of their own, such as collected writings or lecture notes, in a thesis, or to expand the article into book-length form for publication. Please see the Journal Publishing Agreement for full details.